FDA Grants Approval Status for Isoproterenol Hydrochloride Application
The FDA has granted an approval status (AP) for ANDA220299, a generic application for Isoproterenol Hydrochloride submitted by ASPIRO.
Asset / Drug
Drug and asset intelligence for ASPIRO with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Beta-agonist
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.